Review ArticleClinical StudiesR
Prediction of Response in Cancer Immunotherapy
DAINIUS CHARACIEJUS, JOHN J.L. JACOBS, VITA PAŠUKONIENĖ, NIJOLĖ KAZLAUSKAITĖ, VITA DANILEVIČIŪTĖ, MYKOLAS MAURICAS and WILLEM DEN OTTER
Anticancer Research February 2011, 31 (2) 639-647;
DAINIUS CHARACIEJUS
JOHN J.L. JACOBS
VITA PAŠUKONIENĖ
NIJOLĖ KAZLAUSKAITĖ
VITA DANILEVIČIŪTĖ
MYKOLAS MAURICAS
In this issue
Anticancer Research
Vol. 31, Issue 2
February 2011
Prediction of Response in Cancer Immunotherapy
DAINIUS CHARACIEJUS, JOHN J.L. JACOBS, VITA PAŠUKONIENĖ, NIJOLĖ KAZLAUSKAITĖ, VITA DANILEVIČIŪTĖ, MYKOLAS MAURICAS, WILLEM DEN OTTER
Anticancer Research Feb 2011, 31 (2) 639-647;
Jump to section
- Article
- Abstract
- Prediction of Response to Bacillus Calmette-Guérin Immunotherapy
- Prediction of Response to Cytokine Therapy
- Prediction of Response to Monoclonal Antibody Therapy
- Prediction of Response to Vaccination Therapy
- Prediction of Response to Adoptive Cell Immunotherapy
- Conclusions and Future Prospects
- Acknowledgements
- References
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- Informatics for Cancer Immunotherapy
- The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
- Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination
- Expanded Effector Memory T-lymphocytes in DBA/2 Mice Do Not Inhibit the Growth of SL2 Tumours